> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Tremfya
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-tremfya/
- Published: 2018-10-17T12:00:00.000Z
- Updated: 2026-09-15T00:38:52.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142606

*Federal Register* notice: FDA has determined the patent extension-related regulatory review period for Janssen Biotech’s Tremfya (guselkumab), indicated for treating adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The review period is 2,968 days, with 2,728 days having occurred during the testing phase and 240 days during the approval phase. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-10-17/pdf/2018-22571.pdf?ref=fdaweb.com).